PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1 Stylesheet Version v1.2 EPAS ID: PAT2983016

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT

CONVEYING PARTY DATA

Name	Execution Date
TAKESHI KANNO	06/20/2014
AKITO TANAKA	06/22/2014
TADASHI SHIMIZU	06/23/2014
TAKASHI NAKANO	06/20/2014
TOMOYUKI NISHIZAKI	06/20/2014

RECEIVING PARTY DATA

Name:	KTN BIOTEC, INC.
Street Address:	2-6, MEGURI 1-CHOME
City:	HIRAKATA-SHI, OSAKA
State/Country:	JAPAN
Postal Code:	573-1171

PROPERTY NUMBERS Total: 1

Property Type	Number
Application Number:	14298400

CORRESPONDENCE DATA

Fax Number: (312)616-5700

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.

Phone: (312) 616-5600

Email: assignments@leydig.com

Correspondent Name: JOHN KILYK, JR.

Address Line 1: LEYDIG, VOIT & MAYER, LTD.

Address Line 2: TWO PRUDENTIAL PLAZA, SUITE 4900

Address Line 4: CHICAGO, ILLINOIS 60601-6731


ATTORNEY DOCKET NUMBER:	717999
NAME OF SUBMITTER:	JOHN KILYK, JR.
SIGNATURE:	/John Kilyk, Jr./
DATE SIGNED:	08/15/2014

Total Attachments: 4

502936418

source=Assignment#page1.tif

PATENT REEL: 033541 FRAME: 0450



PATENT REEL: 033541 FRAME: 0451

ASSIGNMENT

WHEREAS, I/WE

- (1) Takeshi KANNO of 3-2-1401 Ryodo-cho, Nishinomiya-shi, Hyogo 662-0841 Japan,
- (2) Akito TANAKA of Forest Park Toyonaka Uenosaka 505, 16-15, Uenosaka 2-chome, Toyonaka-shi, Osaka 560-0012 Japan,
- (3) Tadashi SHIMIZU of 11-4-901, Ninomiya-cho 1-chome, Chuo-ku, Kobe-shi, Hyogo 651-0093 Japan,
- (4) Takashi NAKANO of 6-21, Morikita-machi 6-chome, Higashinada-ku, Kobe-shi, Hyogo 658-0001 Japan, and
- (5) Tomoyuki NISHIZAKI of 3-14, Katsuragi 2-chome, Kita-ku, Kobe-shi, Hyogo 651-1223 Japan

hereinafter referred to as Assignor, have invented a certain invention entitled:

NOVEL ANTICANCER AGENT

for which invention an application (provisional or non-provisional) for a U.S. patent was filed on June 6, 2014, under U.S. Application No. 14/298,400, and

WHEREAS, KTN BioTec, Inc. of 2-6, Meguri 1-chome, Hirakata-shi, Osaka 573-1171 Japan, hereinafter referred to as Assignee, is desirous of acquiring the entire right, title, and interest in, to, and under the invention described in the patent application, including the entire priority right derived from the application,

Now, Therefore, for good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged,

Assignor assigns and transfers to Assignee and Assignee's legal representatives, successors, and assigns the entire right, title, and interest in, to, and under the invention, the referenced patent application, other such applications (e.g., provisional applications, non-provisional applications, continuations, continuations-in-part, divisionals, reissues, reexaminations, national and regional phase applications, petty patent applications, and utility model applications) that may be filed in the U.S. and/or any country foreign to the U.S. on the invention, the patents that may issue thereon, and the patents as may be modified as the result of applicable procedures (e.g., supplemental examinations, ex parte reexaminations, inter partes reviews, post-grant reviews, and oppositions),

Assignor conveys to the Assignee the right to make applications in Assignee's own behalf for protection of the invention in the U.S. and countries foreign to the U.S. and to claim priority to the referenced patent application and other such applications that may be filed in the

Leydig, Voit & Mayer

Page 1 of 4

PATENT REEL: 033541 FRAME: 0452 In re Appln. of KANNO et al. Attorney Docket No. 717999

U.S. or any country foreign to the U.S. on the invention under the Patent Cooperation Treaty, the Paris Convention, and any other international arrangements,

Assignor will not execute any writing or do any act conflicting with the terms of this assignment,

Assignor will at any time upon request, without further or additional consideration, but at the expense of the Assignee, execute such additional assignments and other writings and do such additional acts as the Assignee may deem necessary or desirable to pursue the patent applications identified herein, including, but not limited to, rendering all necessary assistance in making applications for and obtaining patents that may issue thereon in the U.S. and any countries foreign to the U.S. on the invention, and in enforcing any rights accruing as a result of such applications or patents, by, for example, executing statements and other affidavits,

Assignor and Assignee agree the terms of this assignment shall bind, and inure to the benefit of, the legal representatives, successors, and assigns of all parties hereto,

Assignor authorizes Assignee to insert in this assignment the number and filing date of the application if the number and filing date of the application are not recited herein at the time of execution of this assignment by any or all of the parties hereto,

Assignor and Assignee agree that U.S. law governs this assignment, and

Assignee acknowledges and accepts this assignment.

IN WITNESS WHEREOF, Assignor has hereunder set his/her hand on the date shown below.

Date	Tune 20, 2014	Takeshi Kanno	
Date	June 20, 2014	Assignor: Takeshi KANNO 12 9	Wishizaki
Date			
		Witness:	

In re Appln. of KANNO et al. Attorney Docket No. 717999	
Date June 22, 2014	Acta and a
	Assignor: Akito TANAKA
Date	Tadashi Shimiya
	Witness: Tadashi SHIMIZU
Data	·
Date	Witness:
Date	Tadashi Shimiyu
	Assignor: Tadashi SHIMIZU
Date June 23, 2014	Alera tank
	Witness: Akito TAWAKA
Date	
	Witness:
	,
Date	- F 1/3 t
	Assignor: Takashi NAKANO
Date	Assignor: Takashi NAKANO LAMII am Tomoyuki Nishizaki Witness: Tomoyuki Nishizaki
	Witness: Tomoyuki NISHIZAKI
Date	
	Witness:
-	

In re Appln. of KANNO et al. Attorney Docket No. 717999	α
Date June 20, 2014	Assignor: Tomoyuki NISHIZAKI
Date	Takeshi kanno Takeshi Kanno Witness: Takeshi KANNO
Date	Witness:

Leydig, Voit & Mayer

RECORDED: 08/15/2014

Page 4 of 4

PATENT

REEL: 033541 FRAME: 0455